Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004915 · ClinicalTrials.gov registry record · Phase 2
Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004915 is a Phase 2 study that has completed, run by Northwestern University.
The verdict
NCT00004915, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Estrogen can stimulate the growth of endometrial cancer cells. Hormone therapy using raloxifene may fight endometrial cancer by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of raloxifene in treating patients who have persistent or recurrent endometrial cancer.
Interventions
- DRUG raloxifene
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-11 |
| Est. Completion | 2000-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004915
The ClinicalTrials.gov registry entry for NCT00004915 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which raloxifene is the first listed.
NCT00004915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004915 about?
NCT00004915 is a clinical study titled "Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer". RATIONALE: Estrogen can stimulate the growth of endometrial cancer cells. Hormone therapy using raloxifene may fight endometrial cancer by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of raloxifene in treating patients who have persistent or recurrent endo...
What is the current status of trial NCT00004915?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-11. Estimated completion is 2000-02.
What interventions are being tested in trial NCT00004915?
The interventions under investigation include: raloxifene (DRUG).
Who is sponsoring clinical trial NCT00004915?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.